Safety and immunogenicity of concomitant administration of a virosomal hepatitis A vaccine (Epaxal®) with DTP, aHib, IPV, OPV and MMR vaccines versus non-concomitant administration in 12 to 15 month-old childre

Not Applicable

Completed

• Conditions: Hepatitis A; Infections and Infestations

• Registration Number: ISRCTN82277382
• Lead Sponsor: Berna Biotech Ltd (Switzerland)

Brief Summary

2007 results in https://pubmed.ncbi.nlm.nih.gov/17721372/ (added 11/01/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2006-01-26
• Study Start: 2006-03-10
• Last Update Posted: 25 January 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 322

Inclusion Criteria

Healthy children between 12 and 15 months old at the time of vaccination

Exclusion Criteria

1. Children that have not received three documented doses of DTP, aHib and polio vaccines during infancy
2. Children that have received a documented dose of MMR during infancy
3. Previous vaccination against hepatitis A
4. Any confirmed or suspected immunosuppressive or immunodeficient condition

Study & Design

• Study Type: Interventional
• Study Design: Not specified